TITLE:
Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
AUTHORS:
Lis Marina de Mesquita Araújo, Sumaya Feguri, Thereza Lopes de Oliveira, Fernanda Batista Pedrosa, Rodrigo Garcez Guimarães, Larissa Bianca Paiva Cunha de Sá, Denise Rosso Tenório Wanderley Rocha, Alberto Krayyem Arbex
KEYWORDS:
Diabetes, GLP-1 Receptor Agonists, Glycemic Control, Extra Glicemic Effects, Weight Loss, Cardiovascular Risk
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.6 No.1,
January
21,
2016
ABSTRACT: GLP-1 receptor agonists
are approved for the treatment of type 2 diabetes, and more recently for
obesity treatment.The
glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced by
intestinal cells, which is involved in insulin secretion and glucagon
suppression. This hormone controls glucose plasma levels and reduces food
intake. Additional effects were reported in slowing gastric emptying and in
inducing satiety.In clinical
practice, theGLP-1 receptor agonistsareassociated with significant reductions
in glycosylated hemoglobin (HbA1c) and weight loss,despite showing a low risk of
hypoglycemia.Beneficial effects
have also been observed on blood pressureand
lipid profile.The most common
side effects associated with GLP-1 receptor agonists are gastro-intestinal
motility disorders, such as nausea, vomiting and diarrhea, which are not
associated withlong-term health
risks. Therefore, GLP-1 receptor agonists represent a relevant medication for
type 2 diabetes, whose benefits may go far beyond glycemic control.